All In Biotech

Drug Trial Radar · NCT05639114

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 436 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

436

Actual

Start

Mar 2, 2023

Primary completion

Mar 26, 2027

Study completion Mar 23, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • IanalumabDrug

    ianalumab s.c. monthly or quarterly

  • PlaceboDrug

    placebo s.c. monthly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants on monthly ianalumab achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4)Time frame: Week 60

Locations

135 sites in 19 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group Llc

    Anniston, Alabama

  • Providence Medical Center

    Burbank, California

  • University of California San Diego

    La Jolla, California

  • Millennium Clinical Trials

    Westlake Village, California

  • University of Colorado

    Aurora, Colorado

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Clinical Res Of W Florida

    Clearwater, Florida

  • GNP Research

    Cooper City, Florida

  • Clinical Research of West Florida Inc

    Tampa, Florida

  • Parris and Associates Rheumatology

    Lawrenceville, Georgia

  • Chicago Clinical Research Inst

    Chicago, Illinois

  • Robert A Hozman MD SC

    Skokie, Illinois

  • Lake Cumberland Rheumatology and In

    New Albany, Indiana

  • Henry Ford Health

    Detroit, Michigan

  • Sahni Rheumatology and Therapy

    West Long Branch, New Jersey

  • Paramount Med Rsrch and Consult LLC

    Middleburg Heights, Ohio

  • University Of Pittsburgh

    Pittsburgh, Pennsylvania

  • Shelby Research LLC

    Memphis, Tennessee

  • Accurate Clinical Research Research

    Baytown, Texas

  • Novel Research LLC

    Bellaire, Texas

  • Accurate Clinical Research

    League City, Texas

  • Epic Medical Research

    Red Oak, Texas

  • Novartis Investigative Site

    San Miguel de Tucumán, Argentina

  • Novartis Investigative Site

    San Miguel, Tucumán Province, Argentina

  • Novartis Investigative Site

    Salvador, Brazil

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil

  • Novartis Investigative Site

    Vitória, Espírito Santo, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil

  • Novartis Investigative Site

    Curitiba, Paraná, Brazil

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil

  • Novartis Investigative Site

    Niterói, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Rousse, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Plovdiv, Bulgaria, Bulgaria

Showing 40 of 135 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.